2025.05.24本文字数:1874,阅读时长大约4.7分钟导读:恒瑞医药H股于5月23日在港交所挂牌,定价每股44.05港元。本次发行获GIC、高瓴资本等豪华基石阵容支持,认购金额超41亿港元。公司计划将94.58亿港元募资用于研发及全球布局,持续推动创新药发展。5月21日,恒瑞医药对外宣布,其H股发行的最终定价为每股44.05港元,并计划于5月23日在香港联交所主板正式挂牌交易。据此前公告,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.